Advertisement
Canada markets closed
  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CAD/USD

    0.7316
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • Bitcoin CAD

    86,193.27
    -1,834.55 (-2.08%)
     
  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     
  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Eagle Point Credit Company Inc. (NYSE:ECC) Q4 2023 Earnings Call Transcript

Eagle Point Credit Company Inc. (NYSE:ECC) Q4 2023 Earnings Call Transcript February 22, 2024

Eagle Point Credit Company Inc.  isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Greetings, and welcome to the Eagle Point Credit Company's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Garrett Edson of ICR. Thank you, Garrett. You may begin.

Garrett Edson: Thank you, and good morning. By now everyone should have access to our earnings announcement and investor presentation, which was released prior to this call and which may also be found on our website at eaglepointcreditcompany.com. As a reminder, before we begin our formal remarks, the matters discussed on this call include forward-looking statements or projected financial information that involve risks and uncertainties that may cause the company's actual results to differ materially from those projected in such forward-looking statements and projected financial information. For further information on factors that could impact the company and the statements and projections contained herein, please refer to the company's filings with the Securities and Exchange Commission.

ADVERTISEMENT

Each forward-looking statement and projection of financial information made during this call is based on information available to us as of the date of this call. We disclaim any obligation to update our forward-looking statements unless required by law. A replay of this call can be accessed for 30 days via the company's website, eaglepointcreditcompany.com. Earlier today, we filed our Form N-CSR, our full year 2023 audited financial statements and our fourth quarter investor presentation with the Securities and Exchange Commission. The financial statements and our fourth quarter investor presentation are also available within the Investor Relations section of the company's website. The financial statements can be found by following the Financial Statements and Reports link, and the investor presentation can be found by following the Presentations and Events link.

I would now turn it over to Tom Majewski, Chief Executive Officer of Eagle Point Credit Company.

Tom Majewski: Thank you, Garrett, and welcome everyone to Eagle Point Credit Company's fourth quarter earnings call. If you haven't done so already, we invite you to download our investor presentation from our website, which provides additional information about the company and our portfolio. I'll start off by saying that the company had both a strong fourth quarter and a great 2023. For the year we generated a GAAP return of equity of 20.79% and a total return on our common stock, assuming reinvestment of distributions of 18.92%. We believe our portfolio remains well positioned for 2024 and also that our portfolio has room for continued upside. The right side of the company's balance sheet is also positioned very well. Some highlights from the fourth quarter include that our net income and realized capital gains totaled $0.33 per common share.

We received recurring cash flows on our portfolio in the fourth quarter of $60.7 million, or $0.82 per common share. This exceeded our aggregate common distributions and expenses for the quarter by $0.14 per share. NAV per share as of December 31 was $9.21. And this is a modest decrease from September 30, but up 2% for the full year. During the quarter, we paid $0.48 per share of cash distributions to our common shareholders, taking the distributions with record dates during the year to $1.86 per share. During the quarter, we continued to actively manage our portfolio opportunistically deploying $34 million in net capital into new investments that we believe will increase the earning power of our portfolio over time. Along with our overall portfolio performance, we continue to prudently raise capital through our at-the-market program, and issued approximately 4.5 million common shares at a premium, generating NAV accretion of $0.03 per share during the quarter.

As of December 31, the weighted average effective yield of our CLO equity portfolio was 16.7% based on amortized cost, and this is an increase from 16.29% at the end of September. The new CLO equity that we purchased during the fourth quarter had a weighted average effective yield of 22.9%, which should help bolster the portfolio's weighted average effective yield prospectively. The company also had a number of meaningful subsequent events that I would like to highlight. We estimated our NAV at January month end to be between $9.22 and $9.32 per share, and that's an increase from yearend. Along with our regular monthly common distributions of $0.14 per share, we also declared additional variable supplemental distributions of $0.02 per share for aggregate monthly common distributions of $0.16 per share through the end of June 2024.

I also want to highlight that inclusive of the January 31 distributions, we've now crossed an important milestone and the cash distributions paid to our shareholders have now totaled $20.15 per share since our IPO in 2014. This means a shareholder who invested in our IPO less than a decade ago has now received over 100%, a full return of invested capital of our IPO price in the form of cash distributions while still owning their shares in Eagle Point. We are immensely proud of this milestone and the value that we have created for shareholders. During the first quarter, we were also pleased to be able to further strengthen our balance sheet, raising an additional $47 million of net proceeds through the issuance of a new Series F term preferred stock due in 2029.

Consistent with our longtime strategy for operating the company, all of our financing remains fixed rate, and we have no financing maturities prior to April 2028. In fact, some of our preferred stock financing is even perpetual, with no set maturity date. We continue to focus most of our investment efforts in the secondary market during the fourth quarter, as the yields and convexity available in the secondary market offered, in our view, better risk adjusted returns than the primary market. We remain focused on finding opportunities to invest in CLO equity with a generally longer reinvestment periods remaining. As a result of our consistently proactive portfolio management, as of December 31, our CLO equity portfolios weighted average remaining reinvestment period, or WARRP stood at 2.4 years well above the market average of 1.6 years.

As we have consistently stated, we believe keeping our weighted average remaining reinvestment period as extended as possible is our best defense against future market volatility. With a notable increase in demand for CLO triple A bonds, we're starting to see a pickup and reset in refinancing activity within the CLO market. We expect to be active in completing resets and refinancing where attractive in order to further increase our portfolio's weighted average remaining reinvestment period and potentially lower our CLOs cost of debt. For the first time in a while, we're also seeing an increase in attractive new issues, CLO equity opportunities, several of which we're pursuing. Before turning the call over to Ken, I'd like to take a moment to highlight Eagle Point Income Company which trades on the New York Stock Exchange under symbol EIC.

EIC primarily invests in CLO Junior debt. For the fourth quarter EIC generated net investment income of $0.56 per share, excluding non--recurring expenses, once again exceeding its common distributions for the quarter. Given our continued confidence in EICs portfolio, we recently raised its monthly common distribution by 11% to $0.20 per share. This is the highest distribution in the company's history. EIC has performed very well over the last few years and we believe remains well positioned to continue generating strong net investment income. We invite you to join EIC's investor call at 11:30 am today, after this call, and to visit the company's website, eaglepointincome.com to learn more. After Ken's remarks, I'll take you through the current state of the corporate loan and CLO markets.

I'll now turn the call over to Ken.

A modern skyscraper in a busy city, symbolizing the prominence of the financial services company.
A modern skyscraper in a busy city, symbolizing the prominence of the financial services company.

Ken Onorio : Thanks, Tom, and thanks to everyone for joining our call. I'll start off by reporting for the fourth quarter of 2023, the company recorded net investment income and realized gains of approximately $25 million or $0.33 per share. This compares to NII and realized gains of $0.35 cents per share in the third quarter of 2023, and NII less realized losses of $0.29 per share in the fourth quarter of 2022. When unrealized portfolio appreciation is included for the fourth quarter, the company recorded GAAP net income of approximately $27 million or $0.37 per share. This compares to GAAP net income of $0.93 per share in the third quarter of 2023 and GAAP net income of $0.17 per share in the fourth quarter of 2022. The company's fourth quarter GAAP net income was comprised of total investment income of $39.4 million, net unrealized appreciation on investments of $10.1 million and realized capital gains of $0.2 million partially offset by expenses of $14.1 million net unrealized appreciation on certain liabilities held at fair value of $8 million and distributions on the Series D preferred stock of $0.5 million.

Additionally, for the quarter ending December 31, 2023, the company recorded another comprehensive loss of $1.2 million. The company's asset coverage ratios at December 31 for preferred stock and debt, calculated pursuant to Investment Company Act requirements were 371% and 551% respectively. These measures are comfortably above the statutory requirements of 200% and 300%. Our debt and preferred securities outstanding at quarter end totaled approximately 27% of the company's total assets, less current liabilities. This is towards the low end of our target range of generally operating the company with leverage between 25% to 35% of total assets under normal market conditions. Last week, we declared distributions for the second quarter in line with our recent distributions.

We will continue to review our variable supplemental distribution on a quarterly basis. Moving on to our portfolio activity this year through February 15, the company received recurring cash flows on its investment portfolio of $50.4 million. This is below our fourth quarter recurring cash flows, as there were higher loan prepayments in the fourth quarter of 2023, which caused a short term buildup of cash on some of our CLOs. In addition, some semi-annual paying loans and bonds and our CLOs underlying portfolios will not make payments again until the second quarter of 2024, which also contributed to the decline in cash flow. As these items are generally timing related we expect portfolio cash flows to be higher in the second quarter, all else equal.

I will now hand the call back over to Tom.

Tom Majewski : Thanks, Ken. I'll now update everyone on the loan and CLO markets. In 2023, the Credit Suisse Leveraged Loan Index generated its best performance in nearly 15 years. It was actually a second best performance on record, with a total return of 13.04% for the full year. The index has continued its positive performance into 2024, and as of February 15, loans were up about 1.14%. During the fourth quarter, we saw only four leveraged loan defaults and that's down from six in the prior quarter. As of yearend, the trailing 12 month default rates stood at 1.53%, remaining well below the long term historic average of 2.7%. While some research desks believe the default rate will rise modestly in 2024, nearly all were completely wrong in 2023.

And we believe that typical loan borrower has far more tools in its toolkit to manage their balance sheet than the average researcher gives credit to. While defaults may actually increase in 2024, we don't expect a spike and believe many forecasters will again miss the mark. During the fourth quarter, approximately 5% of all leveraged loans, or about 21% annualized repaid at par. This represents a modest quarter-over-quarter increase, and importantly provides our CLOs with valuable par dollars to reinvest in today's discounted loan market. With a large number of high quality issuers continuing to trade at discounted prices, CLO collateral managers remain very well positioned to improve underlying loan portfolios through relative value trading in the secondary market.

Loan repayments make this even easier. Additionally, most loan issuers remain very proactive in tackling their near term maturities in an effort to further extend the term of their debt. Some borrowers even offer lenders a higher spread and new OID in order to lengthen out their maturities on their newly refinanced loans. As a result, our portfolio continues to have numerous opportunities to build par and increase our weighted average spread, which in turn increases the excess spread we receive on our CLO equity portfolio. On a look through basis, the weighted average spread of our CLOs underlying loan portfolios was 3.79% at the end of the year. This is comparable to September, but is a healthy 21 basis point increase over the last 21 months.

Meanwhile spreads on debt tranches issued by our CLOs that were locked in 21 months ago, remain unchanged and actually have the potential to tighten if we're able to refinance or reset our CLO debt. Triple C concentrations within our portfolios stood at around 7.4% as of December 31, and the percentage of loans trading below 80 stood at around 4.5%. Our portfolios weighted average Junior over collateralization cushion was 4.28% as of December 31. This gives us ample room to withstand any potential downgrades or losses. Our portfolio's OC cushion remains much higher than the market average, which stood at 3.31% at the end of the year. In terms of new CLO issuance, we saw $32 billion of issuance in the fourth quarter and $116 billion for the full year, once again eclipsing the $100 billion mark.

We believe that over 80% of the volume in 2023, however, was backed by captive CLO funds, which are generally less return sensitive than investors like us. 2024 has started off strong, with a very active January for CLO issuance as triple A's tightened significantly. While secondary CLO equity can vary, CLO equity arbitrage has improved enough that the company has invested in a number of attractive new issues CLOs during the first quarter. We haven't done much of that in some time. As we've consistently noted, its environment of loan price volatility, where we believe CLO structures and CLO equity in particular, are set up well to buy loans at discounts to par with very stable financing structure, using par pay-downs from other loans to outperform the broader corporate debt markets over the medium term as they have in the past.

I'll conclude the call with the following highlights. We generated net investment income and realized capital gains for the quarter of $0.33 per weighted average common share. We continue to receive robust cash flows on our portfolio in the fourth quarter that exceeded our common distributions and expenses. We sourced a number of new investments with very attractive yields, investing $34 million of net capital during the quarter. Our portfolio continues to maintain a weighted average remaining reinvestment period that's significantly longer than the market average. Our existing regular monthly common distributions and our variable supplemental distributions were declared and continued through June of 2024. We further strengthened our liquidity position, generating NAV accretion of $0.03 per share through our ATM program.

And in the first quarter, we generated $47 million of net new capital from the issuance of the Series F term preferred stock. As of February 15 we had about $52 million of cash available to deploy into new investments. And we've been very active in sourcing investments which should provide dry powder. Importantly, we continue to maintain 100% fixed rate financing, with no financing maturities before 2028. And this gives us protection from any further increase in interest rates, and locks us into an attractive cost of capital for many years to come. We have a strong pipeline of primary and secondary CLO equity investments that we're evaluating. In addition, we're carefully looking at many CLOs in our portfolio in evaluating the possibility to refinance or reset them, which if successful, would lock additional upside in our portfolio in 2024.

We believe the company's investment portfolio continues to be very well-positioned given our proactive management, the portfolio's weighted average remaining reinvestment period, its strong OC cushions and its high recurring cash flows. We remain opportunistic and proactive as we manage our investment portfolio, always with a long term mindset. We thank you for your time and interest in Eagle Point. Ken and I will now open the call to your questions. Operator?

See also 15 Countries With The Highest Labor Shortages In Europe and 15 Most Expensive Medical Treatments/Procedures In The World.

To continue reading the Q&A session, please click here.